{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:22:12Z","timestamp":1783059732799,"version":"3.54.6"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Landmark trials have established the surgical feasibility of neoadjuvant immunotherapy plus chemotherapy (NICT) in gastric and esophageal cancers, yet data specific to the narrow anatomical confines of the gastroesophageal junction (GEJ) remain limited. This study aimed to compare postoperative morbidity between patients receiving NICT and those receiving neoadjuvant chemotherapy (NCT) alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective cohort study included consecutive patients with locally advanced GEJ adenocarcinoma (Siewert II\/III) undergoing curative resection after NICT (n=140) or neoadjuvant chemotherapy alone (NCT, n=260). Propensity score matching (1:1) balanced baseline characteristics, including dMMR\/MSI-H status and surgical approach, yielding 120 matched pairs. The primary outcome was major complications (Clavien-Dindo \u2265III). Secondary outcomes included specific surgical complications, immune-related adverse events (irAEs), and interval to surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, NICT was associated with improved major pathological regression (58.3% vs. 45.8%; p=0.028). The primary endpoint was not significantly different between NICT and NCT cohorts (25.8% vs. 22.5%; p=0.538). Critically, no differences were observed in specific technical complications, including anastomotic leak (11.7% vs. 10.0%), conduit failure (3.3% vs. 2.5%), or pulmonary events. irAEs occurred in 13.3% of the NICT cohort without delaying surgical intervention. Multivariable and sensitivity analyses confirmed NICT was not an independent predictor of morbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This analysis provides anatomically focused evidence that the addition of immunotherapy to neoadjuvant chemotherapy for GEJ adenocarcinoma is not associated with a statistically significant increase in risk of major postoperative morbidity, anastomotic failure, or operative complexity. While larger randomized trials remain the gold standard, these findings support the extrapolation of established safety data to the technically demanding GEJ location.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1806803","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:40:57Z","timestamp":1783057257000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Does adding immunotherapy to neoadjuvant chemotherapy increase postoperative morbidity in gastroesophageal junction adenocarcinoma? A propensity score-matched study"],"prefix":"10.3389","volume":"17","author":[{"given":"Huiliang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Du","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbin","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01573-8","article-title":"Expression of therapy target molecules in esophagogastric junction and Barrett's adenocarcinoma","volume":"28","author":"Abe","year":"2025","journal-title":"Gastric Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2024.24.e20","article-title":"Diffuse-type histology is prognostic for all Siewert types of gastroesophageal adenocarcinoma","volume":"24","author":"Mahuron","year":"2024","journal-title":"J Gastric Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/edbk-26-515500","article-title":"Organ preservation for gastroesophageal junction and gastric cancers: Ready for primetime","volume":"46","author":"Mehtsun","year":"2026","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1502611","article-title":"The efficacy of neoadjuvant immunotherapy in gastric cancer, adenocarcinoma of the esophagogastric junction, and esophageal cancer: a meta-analysis","volume":"14","author":"Qian","year":"2024","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113370","article-title":"Treatment of gastric adenocarcinoma: A rapidly evolving landscape","volume":"195","author":"Taieb","year":"2023","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1342162","article-title":"Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35561","article-title":"Combination of immune checkpoint inhibitors and radiotherapy in locally advanced esophagogastric junction adenocarcinoma: A review","volume":"130","author":"Abyaneh","year":"2024","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf157","article-title":"Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis","volume":"30","author":"Anjum","year":"2025","journal-title":"Oncologist"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znac231.022","article-title":"Postoperative and pathological outcomes of CROSS and FLOT as neoadjuvant therapy for esophageal and junctional adenocarcinoma: An international cohort study from the Oesophagogastric Anastomosis Audit (OGAA)","volume":"277","year":"2023","journal-title":"Ann Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.gassur.2024.01.040","article-title":"Contemporary outcomes for resected type 1-3 gastroesophageal junction adenocarcinoma: a single-center experience","volume":"28","author":"Stiles","year":"2024","journal-title":"J Gastrointest Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1631260","article-title":"Development and validation of a machine learning model for predicting early postoperative complications after radical gastrectomy","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12780","article-title":"Short-term postoperative complications and prognostic factors in patients with adenocarcinoma of the esophagogastric junction","volume":"9","author":"Zhang","year":"2018","journal-title":"Thorac Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03720-5","article-title":"Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis","volume":"148","author":"Plum","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26601","article-title":"Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer","volume":"43","author":"Mays","year":"2021","journal-title":"Head Neck"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2017.0761","article-title":"Immune regulation of skin wound healing: Mechanisms and novel therapeutic targets","volume":"7","author":"Larouche","year":"2018","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110511","article-title":"Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery","volume":"51","author":"Barjot","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24179","article-title":"The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality","volume":"113","author":"Fuentes","year":"2016","journal-title":"J Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.03.003","article-title":"Perioperative complications and oncologic outcomes of nephrectomy following immune checkpoint inhibitor therapy: A multicenter collaborative study","volume":"6","author":"Yip","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-024-03576-6","article-title":"The short-term efficacy and safety of neoadjuvant Sintilimab combined with chemotherapy for resectable gastroesophageal junction adenocarcinoma","volume":"410","author":"Chen","year":"2024","journal-title":"Langenbecks Arch Surg"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.10.022","article-title":"Laparoscopic versus open transhiatal approach for adenocarcinoma of the esophagogastric junction: A systematic review and meta-analysis","volume":"47","author":"Chen","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"B24","article-title":"Related factors of postoperative complications of radical resection for adenocarcinoma of esophagogastric junction","volume":"25","author":"Lei","year":"2022","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-0204","article-title":"ILUSTRO: Phase II multicohort trial of Zolbetuximab in patients with advanced or metastatic Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma","volume":"29","author":"Klempner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cllc.2023.08.017","article-title":"Impact of neoadjuvant immune checkpoint inhibitors on surgery and perioperative complications in patients with non-small-cell lung cancer: A systematic review","volume":"24","author":"Takada","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/biom11050700","article-title":"Immunology of acute and chronic wound healing","volume":"11","author":"Raziyeva","year":"2021","journal-title":"Biomolecules"},{"key":"B28","article-title":"Gastrocutaneous fistula in a patient with locally recurrent MSI-high colorectal cancer: Local complications arising from therapeutic response to immune checkpoint blockade","volume":"37","author":"Greene","year":"2017","journal-title":"Anticancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403570","article-title":"Wound healing: insights into autoimmunity, ageing, and cancer ecosystems through inflammation and IL-6 modulation","volume":"15","author":"Lacina","year":"2024","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-025-13589-z","article-title":"Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1806803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:40:58Z","timestamp":1783057258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1806803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1806803"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1806803","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"article-number":"1806803"}}